Although PARP inhibitors have been utilized in HR-deficient tumors (e.g., ovarian tumors with BRCA mutations), there is evidence that PTEN plays a role in the HR pathway through upregulation of RAD51, thereby decreasing double-stranded breaks and maintaining genomic stability [22,23,24]. Here, PTEN is linked to ovarian neoplasm.